Trevi Therapeutics, Inc. Deferred Tax Liabilities, Gross
Trevi Therapeutics, Inc. (TRVI) had Deferred Tax Liabilities, Gross of $183.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-17
- 2025-12-31: Deferred Tax Liabilities, Gross $183.00K.
- 2024-12-31: Deferred Tax Liabilities, Gross $351.00K.
- 2023-12-31: Deferred Tax Liabilities, Gross $552.00K.
- 2022-12-31: Deferred Tax Liabilities, Gross $220.00K.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $183.00K 10-K · filed 2026-03-17 |
| 2024-12-31 | $351.00K 10-K · filed 2026-03-17 |
| 2023-12-31 | $552.00K 10-K · filed 2025-03-18 |
| 2022-12-31 | $220.00K 10-K · filed 2024-03-20 |
| 2021-12-31 | $35.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | $61.00K 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |